"We are very much in shock and grief by this sudden loss of our colleague and friend, and our immediate thoughts go out to John's family," said
Threshold does not expect that Dr. Curd's passing will have an impact on its ongoing or planned clinical trials.
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Denise T. PowellSr. Director, Corporate Communications Threshold Pharmaceuticals, Inc.650-474-8206 email@example.com
News Provided by Acquire Media